Header
We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Q4 2020 Investor Presentation

Investors Event Calendar

View recent presentations and learn more about upcoming events.


October 26, 2021
Third quarter results 2021

Learn More

Q4 2020 Investor Presentation

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

Learn More

ESG Updates: July 22, 2021 (PDF 1.8 MB) | Apr 28, 2021 (PDF 0.3 MB) | Jan 27, 2021 (PDF 0.5 MB) | Oct 28, 2020 (PDF 0.5 MB)
Latest updates: Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessments Webinars


We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.

 


Novartis ESG Investor Day 2021

Novartis shared progress on its most material ESG topics.

Watch highlights

Read the press release

Download slide deck (PDF 9.6 MB)

 

 

Q3 2021 Results


Third quarter results 2021

October 26, 2021
Basel, Switzerland

Watch the webcast
14:00 CEST | 13:00 BST | 08:00 EDT

 


 

Stocks

 

Pulse Updates

September 28, 2021

FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

Read More

September 03, 2021

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients

Read More

 

September 02, 2021

Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee

Read More

Aug 30, 2021

Novartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes

Read More


Students at Morehouse School of Medicine

Novartis COVID-19 Information Center

Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.

Enter the Information Center

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.

 


Stay Up-to-Date

 


 

Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland